← Pacific Biosciences of California overview

Pacific Biosciences of California vs Illumina: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pacific Biosciences of California (PACB)

Q3 2026
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

September 2026
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

Latest
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

Illumina Inc (ILMN)

Q3 2026
▲2▼1

Illumina Surges on Earnings Beat, S&P 500 Entry, Biotech Boom

  • Earnings Beat and Raised Guidance Illumina beat earnings and raised guidance, with revenue up 4.8% to $1.09 billion. Clinical sequencing demand stayed strong, growing 20% outside China, and NovaSeq X placements topped 80 units.

    This point explains the fundamental business strength that drove the stock higher.

  • S&P 500 Inclusion and Biotech Boom The stock gained 46% amid a biotech boom, and Illumina joined the S&P 500, attracting index-fund demand. Eli Lilly joined its Billion Cell Atlas, and Merck/Moderna's cancer vaccine success boosted shares 15.6%.

    This point captures the market and partnership catalysts that amplified the stock's rise.

  • Roche Launches Cheaper Competing Sequencer Roche launched a competing sequencer at $750,000, well below Illumina's $985,000–$1.25 million, threatening its ~70% market share and potentially forcing price cuts or slower sales. Analysts expect gradual share erosion rather than collapse.

    This point highlights the main competitive threat that could pressure future growth.

August 2026
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

Latest
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

July 2026
▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.